Eulav Asset Management buys $25,887,360 stake in Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals (ALXN) : Eulav Asset Management scooped up 83,000 additional shares in Alexion Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 194,000 shares of Alexion Pharmaceuticals which is valued at $25,887,360.Alexion Pharmaceuticals makes up approximately 1.36% of Eulav Asset Management’s portfolio.

Other Hedge Funds, Including , Capstone Investment Advisors reduced its stake in ALXN by selling 17,375 shares or 67.41% in the most recent quarter. The Hedge Fund company now holds 8,400 shares of ALXN which is valued at $1,120,896. Alexion Pharmaceuticals makes up approx 0.08% of Capstone Investment Advisors’s portfolio.Stephens Inc Ar boosted its stake in ALXN in the latest quarter, The investment management firm added 673 additional shares and now holds a total of 2,432 shares of Alexion Pharmaceuticals which is valued at $333,452. Alexion Pharmaceuticals makes up approx 0.01% of Stephens Inc Ar’s portfolio.Fortaleza Asset Management Inc reduced its stake in ALXN by selling 2,250 shares or 22.88% in the most recent quarter. The Hedge Fund company now holds 7,585 shares of ALXN which is valued at $1,039,979. Alexion Pharmaceuticals makes up approx 0.80% of Fortaleza Asset Management Inc’s portfolio.

Alexion Pharmaceuticals closed down -0.23 points or -0.18% at $125.63 with 13,35,715 shares getting traded on Thursday. Post opening the session at $125.9, the shares hit an intraday low of $123.79 and an intraday high of $126.42 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Alexion Pharmaceuticals reported $1.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $1.17. The company had revenue of $753.10 million for the quarter, compared to analysts expectations of $743.05 million. The company’s revenue was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.44 EPS.

Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Reiterated by Stifel on Jul 29, 2016 to “Buy” and Lowered the Price Target to $ 182 from a previous price target of $195 .Shares were Reiterated by Barclays on Jul 29, 2016 to “Equal Weight” and Lowered the Price Target to $ 150 from a previous price target of $165 .RBC Capital Mkts Initiated Alexion Pharmaceuticals on Jul 13, 2016 to “Outperform”, Price Target of the shares are set at $188.

Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Alexion Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Alexion Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.